References
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71(3):660–249.
- American Cancer Society. Key statistics for lung cancer [Internet]. [updated 12 January 2021; cited 14 September 2021]. Available from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.
- National Cancer Institute. SEER Cancer Statistics Review, 1975–2015 [Internet]. [updated April 2018; cited 5 November 2021]. Available from: https://seer.cancer.gov/csr/1975_2015/.
- Borghaei H, Gettinger S, Vokes EE, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–733.
- Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–1684.
- Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623–1640.
- Dong J, Li B, Lin D, et al. Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. 2019;10:230.
- OPDIVO (nivolumab) [prescribing information]. Princeton (NJ): Bristol Myers Squibb; 2021.
- YERVOY (ipilimumab) [prescribing information]. Princeton (NJ): Bristol Myers Squibb; 2020.
- Das R, Verma R, Sznol M, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950–959.
- Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086.
- Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031.
- Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376(25):2415–2426.
- Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830.
- Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6(5):661–674.
- Bracci L, Schiavoni G, Sistigu A, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15–25.
- Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015;75(23):5034–5045.
- Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198–211.
- National Comprehensive Cancer Network. Non-small cell lung cancer (version 5.2021) [Internet]. [updated May 2021; cited 14 September 2021]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
- Bremner KE, Krahn MD, Warren JL, et al. An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data. Palliat Med. 2015;29(10):918–928.
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- Latimer NR. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data [Internet]. School of Health and Related Research, University of Sheffield, UK: [updated 2021 Jul 8]. Available from: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf.
- National Institute for Health and Care Excellence. NICE technology appraisal guidance [TA531]: pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [Internet]. [updated 2021 Feb 13]. Available from: https://www.nice.org.uk/guidance/ta531/resources/pembrolizumab-for-untreated-pdl1positive-metastatic-nonsmallcell-lung-cancer-pdf-82606895901637.
- Chaudhary MA, Lubinga SJ, Smare C, et al. Cost-effectiveness of nivolumab in patients with NSCLC in the United States. Am J Manag Care. 2021;27(8):e254–e260.
- Huang M, Lou Y, Pellissier J, et al. Cost effectiveness of pembrolizumab vs. standard-of-care chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in the United States. Pharmacoeconomics. 2017;35(8):831–844.
- Insinga RP, Vanness DJ, Feliciano JL, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. J Med Econ. 2018;21(12):1191–1205.
- Insinga RP, Vanness DJ, Feliciano JL, et al. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US. Curr Med Res Opin. 2019;35(7):1241–1256.
- Latimer NR. Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–754.
- Ramalingam SS, Ciuleanu TE, Pluzanski A, et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: three-year update from CheckMate 227 part 1. J Clin Oncol. 2020;38(15_suppl):9500–9500.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
- Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–1290.
- Quinn C, Garrison LP, Pownell AK, et al. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. J Immunother Cancer. 2020;8(2):e000648.
- Jackson C, Stevens J, Ren S, et al. Extrapolating survival from randomized trials using external data: a review of methods. Med Decis Making. 2017;37(4):377–390.
- Latimer NR. Response to "survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach" by Bagust and Beale. Med Decis Making. 2014;34(3):279–282.
- Rutherford MJ, Lambert PC, Sweeting MJ, et al.. NICE DSU technical support document 21: flexible methods for survival analysis [Internet]. [updated 2021 Jan 23; cited 2021 Sep 14]. Available from: http://nicedsu.org.uk/wp-content/uploads/2020/11/NICE-DSU-Flex-Surv-TSD-21_Final_alt_text.pdf.
- Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–526.
- Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–1641.
- Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90–95.
- Peng Y, Zeng X, Peng L, et al. Cost-effectiveness of nivolumab plus ipilimumab combined with two cycles of chemotherapy as first-line treatment in advanced non-small cell lung cancer. Adv Ther. 2021;38(7):3962–3972.
- Courtney PT, Yip AT, Cherry DR, et al. Cost-effectiveness of nivolumab-ipilimumab combination therapy for the treatment of advanced non-small cell lung cancer. JAMA Netw Open. 2021;4(5):e218787.
- Li J, Zhang T, Xu Y, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC. Immunotherapy. 2020;12(14):1067–1075.
- Hu H, She L, Liao M, et al. Cost-effectiveness analysis of nivolumab plus ipilimumab vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer. Front Oncol. 2020;10:1649.
- FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC Internet]. White Oak (MD): U.S. Food and Drug Administration; [updated 2018 Dec 14; cited 2021 Sep 14]. Available from: https://www.fda.gov/drugs/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc.
- FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS ≥1%) [Internet]. White Oak (MD): U.S. Food and Drug Administration. [updated 2019 Apr 11; cited 2021 Sep 14]. Available from: https://www.fda.gov/drugs/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1.
- FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations [Internet]. White Oak (MD): U.S. Food and Drug Administration; [updated 2019 Dec 5; cited 2021 Sep 14]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk.